Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Illumina's TruSight Tumor Content; Ambry's Tumor Profiling Services; More


Illumina has launched TruSight Tumor Content, an amplicon-based panel that targets 26 oncogenes and tumor suppressor genes selected associated with common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer. In enables detection of minor alleles below 5 percent frequency, according to the company. The panel is available for order now with shipment expected in the second quarter.

Ambry Genetics is now offering somatic variant profiling services from formalin-fixed, paraffin-embedded tissue on its Illumina sequencing platforms. The assay covers relevant hotspot regions of 26 genes associated with lung, colon, melanoma, gastric, and ovarian cancers.

GE Healthcare has launched a next-generation sequencing assay focused on solid tumors through its Clarient Diagnostics business that will target 26 cancer-related genes. The company will offer the assay for use in clinical trials.

Genewiz has launched OncoGxOne Discovery cancer panels, proprietary gene panels designed for all major cancer types. The panels can detect point mutations, indels, gene fusions, and copy number variants, according to the company.

Life Technologies' Ion Torrent has launched Oncomine Gene Browser and Ion Reporter Oncomine.

Oncomine Gene Browser enables researchers to characterize genes of interest across multiple parameters, including gene expression, DNA copy number, and mutation data, and is geared toward researchers working with small numbers of genes.

The Ion Reporter Oncomine workflow provides access to curated next-generation sequencing data from 4,000 matched tumor and normal pairs and is designed to assist with interpreting variants from data obtained on the Ion Torrent sequencing platforms. It will be available at no charge for an introductory period.